Preview: SMi’s 20th Annual Pain Therapeutics – ONLINE CONFERENCE
Posted in on 12th Mar 2020
Preview: Discover Cutting Edge Research and Novel Therapeutics in the Pipeline at the Annual Pain Therapeutics Conference
Conference details: 11 and 12 May 2020
Location: Remote Access Only – download access info here.
Conflict of interest statement: Information supplied by SMi Pharma
Programme download: www.acnr.co.uk
The 20th Annual Pain Therapeutics Conference will overview the current state of pain treatment starting with research essentials including choosing the right preclinical models to overviewing clinical success up to date, highlighting cutting-edge research and evaluating the potential of drug candidates in the pipelines of leading pharmaceuticals.
This year we are introducing the Pain Research Essentials theme to closely observe analgesics drug development from a preclinical point of view. Within this theme talks will address the latest biomarker discoveries, bridging the translational gap, differences of pain pathology across sexes and consequently, the need for distinct gender animal models. This will be topped with a panel discussion around novel drug targets in neuropathic pain treatment.
Presentations on clinical stage research will highlight current struggles of opioid-based treatments and discuss results of treatments with non-opioid targets; such as the recently researched cannabinoid receptor 2, nociception/orphanin FQ peptide (NOP) receptor, ENKephalinase and NGF receptors. Furthermore, neuro-immune interactions and their role in pain pathology will be discussed as an anticipated approach for providing more effective therapy for chronic pain. Additionally, the therapeutic efficacy of neurotoxins will be addressed exploring novel botulinum-based constructs.
Join SMi’s leading Pain Therapeutics Conference which will explore the cutting-edge research of novel therapeutics in the pipeline of leading pharmaceutical companies and discuss solutions for the challenges of understanding pain as a heterogenous disease and the diverse treatment approaches it requires.
WHO SHOULD ATTEND?
Chief Executive Officer, Chief Scientific Officers, Chief Medical Officers, Managing Directors, CEO, Head of Department, Principal Research Scientists, Clinical lead, Clinical Operations in the following fields:
- Pain and Migraine
- Chronic Pain
- Neuropathic Pain
- Analgesic pre-clinical development
- Anaesthesia and Pain Management
- CNS clinical trials
- Ion Channel Pharmacology
- Pharmacology Intelligence
- Translational science
- Drug development
- Exploratory development
Download the programme here.Download this Article